BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17218068)

  • 1. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation.
    Huang XS; Zhao SP; Hu M; Luo YP
    Med Hypotheses; 2007; 69(1):136-40. PubMed ID: 17218068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells.
    Xu N; Zhang XY; Dong X; Ekström U; Ye Q; Nilsson-Ehle P
    Biochem Biophys Res Commun; 2002 Apr; 292(4):944-50. PubMed ID: 11944906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoM: gene regulation and effects on HDL metabolism.
    Nielsen LB; Christoffersen C; Ahnström J; Dahlbäck B
    Trends Endocrinol Metab; 2009 Mar; 20(2):66-71. PubMed ID: 19200746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein M: progress in understanding its regulation and metabolic functions.
    Christoffersen C; Dahlbäck B; Nielsen LB
    Scand J Clin Lab Invest; 2006; 66(7):631-7. PubMed ID: 17101555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
    Wolfrum C; Poy MN; Stoffel M
    Nat Med; 2005 Apr; 11(4):418-22. PubMed ID: 15793583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
    Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
    J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory mechanisms in atherosclerosis.
    Wolf D; Stachon P; Bode C; Zirlik A
    Hamostaseologie; 2014; 34(1):63-71. PubMed ID: 24343521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling immune system control of atherogenesis.
    Pappalardo F; Musumeci S; Motta S
    Bioinformatics; 2008 Aug; 24(15):1715-21. PubMed ID: 18556669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein M.
    Luo G; Zhang X; Nilsson-Ehle P; Xu N
    Lipids Health Dis; 2004 Oct; 3():21. PubMed ID: 15461812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein M: Research Progress and Clinical Perspective.
    Luo G; Xu N
    Adv Exp Med Biol; 2020; 1276():85-103. PubMed ID: 32705596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein M: Research progress, regulation and metabolic functions (Review).
    Huang LZ; Gao JL; Pu C; Zhang PH; Wang LZ; Feng G; Zhang Y
    Mol Med Rep; 2015 Aug; 12(2):1617-24. PubMed ID: 25901639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The double jeopardy of HDL.
    Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Hama S; Hough G; Bachini E; Grijalva VR; Wagner AC; Shaposhnik Z; Fogelman AM
    Ann Med; 2005; 37(3):173-8. PubMed ID: 16019715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness.
    Dullaart RP; Plomgaard P; de Vries R; Dahlbäck B; Nielsen LB
    Clin Chim Acta; 2009 Aug; 406(1-2):129-33. PubMed ID: 19539616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese.
    Jiao GQ; Yuan ZX; Xue YS; Yang CJ; Lu CB; Lu ZQ; Xiao MD
    Clin Biochem; 2007 Oct; 40(15):1108-12. PubMed ID: 17674965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
    Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.
    Loppnow H; Werdan K; Buerke M
    Innate Immun; 2008 Apr; 14(2):63-87. PubMed ID: 18713724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein M promotes mobilization of cellular cholesterol in vivo.
    Elsøe S; Christoffersen C; Luchoomun J; Turner S; Nielsen LB
    Biochim Biophys Acta; 2013 Jul; 1831(7):1287-92. PubMed ID: 24046869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen upregulates hepatic apolipoprotein M expression via the estrogen receptor.
    Wei J; Shi Y; Zhang X; Feng Y; Luo G; Zhang J; Mu Q; Tang Y; Yu Y; Pan L; Nilsson-Ehle P; Xu N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1146-51. PubMed ID: 21816233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression pattern of apolipoprotein M during mouse and human embryogenesis.
    Zhang XY; Jiao GQ; Hurtig M; Dong X; Zheng L; Luo GH; Nilsson-Ehle P; Ye Q; Xu N
    Acta Histochem; 2004; 106(2):123-8. PubMed ID: 15147633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
    Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA
    J Am Coll Cardiol; 2009 Mar; 53(11):962-71. PubMed ID: 19281927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.